Vaccine Info

AnGes Coronavirus Vaccine

AnGes Coronavirus Vaccine Description

AnGes Coronavirus vaccine candidate is a plasmid DNA vaccine that disables the connection between the protein spikes of the coronavirus and receptors in human cells.

AnGes has a headstart in the potential COVID-19 vaccine development by repurposing its hypertension vaccine that had already passed through high safety and regulatory standards.

Early results from tests in mice show increased antibody production, and tests in 30 human volunteers are due to begin in July, with the first results expected in September.

AnGes Coronavirus Vaccine Indication

AnGes Coronavirus Vaccine candidate is indicated to prevent COVID-19 disease associated with the SARS-CoV-2 vaccine.

AnGes Coronavirus Vaccine News

June 30, 2020 - The first clinical trial on humans of a potential vaccine for the new coronavirus has begun. AnGes vaccine candidate will inject a genetically engineered circular DNA into the body that produces "spike proteins," which are a characteristic of the coronavirus, according to the company. When such proteins are made, the body's immune system is stimulated to make antibodies against the virus.

June 11, 2020 - Japanese biotech AnGes expects its coronavirus vaccine to be ready as early as the first half of 2021 if it can overcome supply chain and production hurdles, the company’s founder has said. “The future of COVID-19 is very mysterious,” said Morishita, adding that any vaccine would likely need constant tweaking as the virus mutates and returns.

AnGes Coronavirus Vaccine Clinical Trials

Early results from tests in mice show increased antibody production, and tests in 30 human volunteers are due to begin in July, with the first results expected in September.